Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ZVSA 
ZyVersa Therapeutics Inc. (ZVSA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/13/2025: ZVSA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20
1 Year Target Price $20
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -71.21% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.30M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 1 | Beta 0.83 | 52 Weeks Range 0.11 - 1.95 | Updated Date 11/14/2025 |
52 Weeks Range 0.11 - 1.95 | Updated Date 11/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.94 |
Earnings Date
Report Date 2025-11-13 | When Before Market | Estimate -0.25 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.75% | Return on Equity (TTM) -112.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1914629 | Price to Sales(TTM) - |
Enterprise Value -1914629 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.21 | Shares Outstanding 8095921 | Shares Floating 7677524 |
Shares Outstanding 8095921 | Shares Floating 7677524 | ||
Percent Insiders 0.03 | Percent Institutions 5.69 |
Upturn AI SWOT
ZyVersa Therapeutics Inc.
Company Overview
History and Background
ZyVersa Therapeutics, Inc. (ZVSA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for patients with inflammatory or fibrotic diseases. Founded in 2015, the company has focused on advancing its lead drug candidates through clinical trials.
Core Business Areas
- Inflammation: Developing therapies for inflammatory diseases, with a focus on renal and metabolic conditions.
- Fibrosis: Developing therapies targeting fibrosis, the scarring of tissues, in various organ systems.
Leadership and Structure
James S. Garner is the current CEO. The company has a board of directors and a management team responsible for research, development, and operations.
Top Products and Market Share
Key Offerings
- VAR 200: A novel inflammasome ASC inhibitor being developed for kidney diseases, including focal segmental glomerulosclerosis (FSGS). Clinical trials are ongoing. Market share information is not publicly available at this stage of development. Competitors are companies developing treatments for FSGS and other kidney diseases, such as Travere Therapeutics.
- Phase 2a NASH: Clinical study of VAR 200 for treatment of NASH. Clinical trials are ongoing. Market share information is not publicly available at this stage of development. Competitors are companies developing treatments for NASH, such as Madrigal Pharmaceuticals.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and strict regulatory requirements. It is driven by the unmet needs for new and improved therapies for various diseases.
Positioning
ZyVersa Therapeutics is positioned as a clinical-stage company focused on novel therapies for inflammatory and fibrotic diseases. Its competitive advantage lies in its inflammasome ASC inhibition technology platform and lead drug candidate VAR 200.
Total Addressable Market (TAM)
The TAM for FSGS and NASH is estimated to be in the billions of dollars. ZyVersa is positioned to capture a portion of this market with successful clinical trials and regulatory approval of its therapies.
Upturn SWOT Analysis
Strengths
- Novel inflammasome ASC inhibition technology platform
- Lead drug candidate VAR 200 in clinical development
- Experienced management team
- Focus on unmet medical needs in inflammatory and fibrotic diseases
Weaknesses
- Clinical-stage company with no approved products
- Limited financial resources
- High risk of clinical trial failures
- Dependence on successful development and commercialization of VAR 200
Opportunities
- Successful clinical trials of VAR 200
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline with new drug candidates
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other pharmaceutical companies
- Lack of funding
Competitors and Market Share
Key Competitors
- TRVN
- GILD
- ICPT
Competitive Landscape
ZyVersa Therapeutics faces competition from other pharmaceutical companies developing therapies for inflammatory and fibrotic diseases. Its competitive advantage will depend on the efficacy, safety, and market acceptance of its therapies.
Growth Trajectory and Initiatives
Historical Growth: As a clinical-stage company, ZyVersa Therapeutics has not yet experienced significant revenue growth. Its growth potential is tied to the successful development and commercialization of its therapies.
Future Projections: Future projections for ZyVersa Therapeutics are highly uncertain and will depend on the outcome of its clinical trials and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing VAR 200 through clinical trials and exploring potential partnerships with larger pharmaceutical companies.
Summary
ZyVersa Therapeutics is a high-risk, high-reward clinical-stage biopharmaceutical company focused on inflammatory and fibrotic diseases. The company's strength lies in its novel inflammasome ASC inhibition technology platform and lead drug candidate VAR 200. Weaknesses include limited financial resources and the inherent risks of clinical development. The company needs to successfully navigate clinical trials and secure partnerships to realize its growth potential.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings, press releases, analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ZyVersa Therapeutics Inc.
Exchange NASDAQ | Headquaters Weston, FL, United States | ||
IPO Launch date 2022-12-12 | Co-Founder, Chairman, CEO & President Mr. Stephen C. Glover | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.zyversa.com |
Full time employees 7 | Website https://www.zyversa.com | ||
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.